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Scaffold Fabrication Technologies and Structure/Function 
Properties in Bone Tissue Engineering
Maurice N. Collins,* Guang Ren,* Kieran Young, S. Pina, Rui L. Reis, and J. Miguel Oliveira
Bone tissue engineering (BTE) is a rapidly growing field aiming to create a 
biofunctional tissue that can integrate and degrade in vivo to treat diseased 
or damaged tissue. It has become evident that scaffold fabrication techniques 
are very important in dictating the final structural, mechanical properties, and 
biological response of the implanted biomaterials. A comprehensive review 
of the current accomplishments on scaffold fabrication techniques, their 
structure, and function properties for BTE is provided herein. Different types 
of biomaterials ranging from inorganic biomaterials to natural and synthetic 
polymers and related composites for scaffold processing are presented. 
Emergent scaffolding techniques such as electrospinning, freeze-drying, 
bioprinting, and decellularization are also discussed. Strategies to improve 
vascularization potential and immunomodulation, which is considered a 
grand challenge in BTE scaffolding, are also presented.
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of interest.[4] Bone tissue engineering 
(BTE) strategies (Figure  1) are showing 
promise to replace lost or damaged bone 
tissue, over more traditional bone grafting 
methods, such as autografts or allografts.
Several scaffold fabrication techniques 
are at the forefront of tissue engineering 
(TE), such as electrospinning, freeze-
drying, bioprinting, and decellularization.[6] 
Combined with these fabrication methods, 
a vast array of materials has been selected 
for BTE. This selection is generally based 
on functional and biological require-
ments of bone tissue, which itself is a 
composite material consisting of inor-
ganic and natural components, organized 
in a highly hierarchical manner. There 
has been a recent shift in thinking from 
bio-inert materials to bioactive materials, focused on naturally 
occurring biopolymers due to their inherent ability to interact 
with growing cells and their ease of chemical modification.[7] 
Recently, biomaterials derived from decellularized extracellular 
matrix have also been applied in BTE scaffolding. Decellularized 
bone extracellular matrix (ECM) maintains the native matrix 
structure, growth factors, and cytokines, thus enhancing cell 
viability and growth for tissue repair and regeneration.[8]
Although a lot of recent research has been conducted on this 
topic, the selection of fabrication methodologies and different 
biomaterials for BTE is still grounded in hypothesis with no 
clear path forward. BTE has been the subject of previous reviews 
focusing on biomaterials,[9] fabrication techniques,[6a,b,10] and 
structural design.[11] However, this review focuses on the evalu-
ation of fabrication methodologies for bone scaffolding, while 
1. Introduction
Tissue engineering aims to develop new biofunctional tis-
sues, to regenerate and repair damaged or diseased tissue. 
The number of orthopedic surgery procedures performed 
worldwide totaled approximately 22.3 million in 2017 and is pro-
jected to approach 28.3 million by 2022.[1] Diseased or damaged 
bone tissue currently places an enormous demand on bone 
substitutes for transplantation, being the second most trans-
planted tissue annually.[2] Typically, bone repair is carried out 
using bone tissue directly from the patient or from compatible 
donors. These treatments are limited to smaller size defects due 
to surrounding tissue supply shortage, donor site morbidity, 
and incompatibility.[3] In order to overcome those limitations, 
fabrication of biomimetic scaffolds is an ever-increasing area 
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providing a commentary for optimum future routes for the 
fabrication of high-performance bone tissue implants. Specific 
attention is paid to the mapping of scaffold structure/property/
processing relationships to biological function, and how clinical 
outcomes may be enhanced via concurrent advancements in 
vascularization, immunomodulation, and osteogenesis.
The first section defines TE in general and BTE in par-
ticular. The second and third sections briefly overview the 
myriad of biomaterials and scaffold fabrication technologies 
available for BTE. The fourth and fifth sections critically and 
comprehensively evaluates scaffold structure/property/func-
tion relationships for bone tissue engineering while providing 
a commentary on optimum future routes for the fabrication 
of high-performance bone tissue implants. This is followed by 
a discussion of the latest concurrent developments relating to 
vascularization, immunomodulation, and osteogenesis. Finally, 
we provide an outlook for the future while emphasizing the 
importance of structure/property/function relationships in 
optimizing clinical outcomes for BTE.
2. Biomaterials for Bone Tissue Engineering
Bone is a highly organized composite material comprised 
by 50–70% inorganic constituents (primarily hydroxyapatite 
(HAp)), 20–40% organic constituents (primarily type I collagen), 
5–10% water, and 3% lipids.[12] At a macro-scale, bone can be 
divided into outer layered hard cortical bone and the spongy 
trabecular bone.[13] Osteoblast cells contribute to the formation 
of new bone in the form of osteoid, which consists of collagen 
and other proteins. Figure 2 illustrates the distribution of these 
materials respective to their scale within the bone structure.
Figure 1. Bone tissue engineering strategies. Reproduced with permission.[5] Copyright 2020, Elsevier.
Figure 2. Hierarchical organization of bone tissue materials. Reproduced with permission.[17] Copyright 2016, Elsevier.
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Biocompatibility of materials and their degradation products 
is also an important consideration in BTE. Scaffolds should 
allow cell attachment, proliferation, and differentiation, while 
being non-cytotoxic and evoke minimal immune response.[5] 
For BTE, bioactivity covers two primary biological processes: 
i) osteoconductivity and ii) osteoinductivity. Osteoconductive 
scaffolds facilitate bone deposition on the surface of the mate-
rial in non-osseous sites, while osteoinductive scaffolds employ 
immature stem cells and direct their differentiation toward 
bone cells such as preosteoblasts.[14]
A wide range of biomaterials have been investigated to bone 
grafts scaffolding, namely inorganic biomaterials, which com-
prise metals (e.g., titanium and its alloys) and bioceramics 
(e.g., calcium phosphates (e.g., HAp and α,β-tricalcium phos-
phate [α,β-TCP]), calcium carbonates, bioactive glasses and 
glass-ceramics, alumina, and zirconia), and a myriad of natural 
(e.g., collagen, gelatin, silk fibroin [SF], chitosan, hyaluronic acid 
[HA], gellan gum [GG] and derivatives, and alginate) and syn-
thetic polymers (e.g., polyurethanes [PU] and polycaprolactone 
[PCL]), as well as their combinations (Table 1). Bioceramics are 
well known for their excellent biocompatibility, osteoconductivity, 
and bioresorbability. Polymers have high mechanical strength 
and stiffness, and benefits are added with natural polymers such 
as biocompatibility and ECM similarities.[15]
The inclusion of cells in fabricated scaffolds is a crucial step 
in the fabrication process, either during the fabrication pro-
cess such as 3D bioprinting, or seeding cells on prefabricated 
scaffolds. Often prefabricated scaffolds are coated with ECM 
derived gels or ECM-like gels to enhance biocompatibility and 
to promote cell seeding.[15,16]
The implanted biomaterials should provide enough 
mechanical stability at the time of implantation, while evoking 
a non-immunogenic response as the biomaterials degrade 
simultaneously with the growth of native tissue.[9b]The bioma-
terials should also facilitate the proliferation and infiltration 
of nearby stem cells as well as osteoblast cells. The selection 
of a biomaterial is driven by the closeness of the mechanical 
properties to those of native bone tissue. For example, cortical 
bone has an elastic modulus of 14–20 GPa, while bioactive glass 
45S5 Bioglass has a reported elastic modulus of 35 GPa, while 
PGA reaches 7 GPa and natural biopolymer collagen fibrils 
≈35 MPa.[6c,18] As a result, thermoplastic polymers with higher 
Table 1. General properties of commonly used biomaterials in BTE.
Material type Materials General properties* Ref.
Inorganic biomaterials—Metals Titanium and its alloys High strength, bioinert, low density, not biodegradable, low modulus of elasticity [20]
Inorganic 
biomaterials—Bioceramics
HAp Biocompatible osteoconductive/osteoinductive, brittle, low mechanical strength, slow 
resorption rate
[21]
β-TCP Biocompatible, highly resorbable, osteoconductive/osteoinductive brittle [21a]
Bioactive glasses Bioactive, high strength and toughness, elastic modulus, wear resistance, fast degradation 
rates which can be overcome by incorporating different ions in the glass structure
[18d,22]
Alumina High hardness, high abrasion resistance, bioinert, excellent biocompatibility, low 
fracture toughness, brittle
[23]
Zirconia Bioinert, excellent fracture toughness, high strength and elastic modulus, wear 
resistance, good thermal shock resistance
[24]
Natural polymers Collagen Non-cytotoxicity, low antigenicity response, crosslinking capacity, enzymatic 
biodegradability, complex structure
[25]
Gelatin Biocompatible, non-immunogenic, biodegradable, liquefies at physiological 
temperatures, poor mechanical properties
[25,26]
SF Biocompatible, elastic, excellent mechanical strength, slow degradability [22b,27]
HA Biodegradable, biocompatible, viscoelastic
Highly hydrophilic, not mechanically stable, slow gelation rate
[28]
Chitosan Biodegradable, good antithrombogenic and hemostatic action, mucoadhesion, analgesic 
effect, antifungal activity, insoluble in water
[21c,29]
GG Thermally reversible gel, biocompatible, excellent strength and stability, ionic gelation [30]
Alginate Gelling and viscosity agent, water-uptake ability, biodegradable [26a,31]
Synthetic polymers PLLA Biodegradable, biocompatible [6c,32]
PLGA Biocompatible, biodegradable [6c,32a]
PCL Biocompatible, biodegradable, excellent mechanical properties [33]





SF/β-TCP; SF/HAp; collagen/BCP Mechanical properties enhancement, high cell attachment and proliferation, increased 
in vivo response and new bone formation
[35]
HAp = hydroxyapatite; β-TCP = β-tricalcium phosphate; SF = silk fibroin; HA = hyaluronic acid; GG = gellan gum; PLLA = poly-l-lactide acid; PLGA = poly-lactic-co-glycolic 
acid; PCL = polycaprolactone; PU = polyurethane; BCP = biphasic calcium phosphate; *We include general properties here as the actual properties are influenced by many 
variables including but not limited to grain size, processing procedure, molecular weight distribution, crosslink density, porosity, etc.
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stiffness range and porous bioceramics are often selected for 
BTE, as they can mimic the load-bearing nature required for 
bone tissue regeneration.[19] The most promising inorganic 
biomaterials, natural and synthetic polymers used in BTE are 
described as follows.
2.1. Inorganic Biomaterials
Inorganic biomaterials (e.g., metals and bioceramics) have been 
widely used to repair and regenerate diseased and damaged 
bone. This type of biomaterials have been particularly applied 
in bone grafts and cements, orthopedic load-bearing coatings 
(hip acetabular cups), and periodontal repair.[36]
Metallic biomaterials such as titanium and its alloys are 
characterized by their high strength, low elastic modulus, and 
low density, while bioceramics have excellent biocompatibility, 
osteoconductivity, and resistance to corrosion.[20,37] Besides, bioce-
ramics are strong in compression but brittle in tension, showing 
compressive strength of ten times the tensile strength.[38]
Among bioceramics, calcium phosphates (HAp and TCP) 
have long been used due to their resemblance to the mineralog-
ical structure of native bone.[21a] TCP, both in its β and α forms, 
has high resorption rate, creating a resorbable network, while 
HAp is the most stable phase under physiological conditions. 
These materials have limited mechanical strength for load-
bearing applications, which can be overcome by combining 
them with polymers. Besides, this type of ceramics can 
easily incorporate several bioactive ions, signaling molecules 
and cells.
Alumina and zirconia are other types of ceramics suc-
cessfully used in orthopedics, particularly for total hip/knee 
arthroplasty, owing their chemical bioinertness, and high 
strength, hardness, cracking, and corrosion resistance.[23,24] 
By combining zirconia and alumina as composites (referred 
to as zirconia toughened alumina [ZTA]) can improve the low 
fracture toughness, wear properties, and low susceptibility of 
degradation of alumina ceramics, thus decreasing the risk of 
impingement and dislocation, and boosted stability.[39]
Bioactive glasses are often used in bone regeneration 
showing faster capability to bond to connective tissues than 
other bioceramics, forming a layer of amorphous calcium 
phosphate or HAp upon implantation.[6c,18d] Furthermore, the 
release of Si, Ca, P, and Na ions from silicate glasses during 
their dissolution can stimulate osteogenesis and neovasculari-
zation/angiogenesis, and enzymatic activity.[40]
2.2. Natural Biopolymers
Natural biopolymers are especially advantageous in com-
parison to synthetic polymers, owing their similarity with the 
ECM, biocompatibility, and biodegradability.[33a,41] Biopolymers 
mostly studied for BTE are proteins (e.g., collagens, gelatin, 
and SF) and polysaccharides (e.g., chitosan, HA, GG, and 
alginate). Varying crosslinking strategies are often employed 
by themselves or in combination with chemical modifications 
to provide control of scaffold stiffness and structure. These are 
discussed further in Section 3.3 below.
Collagens and gelatin display similar physical properties and 
are extensively used across biomedical applications because of 
their excellent biodegradability, biocompatibility, and immuno-
genicity.[42] Collagens makes up one third of the body’s protein 
being the most abundant polymer found in bone tissue.[43] Over 
more than 29 types of collagen have been documented and are 
being widely applied in tissue engineering due to its ability 
for tissue formation and cell growth.[44] Across the different 
types of collagen, type I is the most prevalent in bone tissue, 
while type II is mostly found in cartilage.[45] Recently, collagen 
derived from marine sources has also attracted attention as 
an alternative to mammalian collagen, because of its low cost 
of production and easiness of extractability from the available 
amount of marine waste residues.[46]
Gelatin is a natural water-soluble protein derived from 
insoluble animal collagen through enzyme processing.[17] There 
are two types of gelatin: Type A that is created via acid treatment, 
and Type B that is processed with an alkaline, or high pH, solu-
tion.[12] Nanofibrous scaffolds comprising of gelatin are primarily 
used in large bone defects repair.[47] A host of reasons deem 
gelatin as a suitable biomaterial for BTE, including: i) biocompati-
bility and biodegradability; ii) elastic nature; iii) lower antigenicity 
when compared to parent protein; iv) excellent cell adhesion, 
and v) accessible functional groups allowing chemical modifi-
cations.[48] It has also the capacity of gel forming, emulsifying, 
foaming, and thickening, depending from collagen type, source, 
and denaturation process. Furthermore, gelatin blends effectively 
with both natural and synthetic polymers that can promote high 
bio-affinity and biomechanical properties of the scaffolds.[47]
Silk obtained from Bombyx mori, mulberry and non-mulberry 
silks, and spiders, have been the mostly explored in tissue 
engineering.[27a] Particular interest has been given to B. mori 
SF, which is a fibrous protein with a semi-crystalline structure 
that affords good mechanical strength and stiffness, high bio-
compatibility, elasticity, and slow degradability. SF is composed 
by two main crystal structures: i) silk I formed alternatively by 
α-helix and β-sheet conformations, and ii) silk II which is an 
anti-parallel β-sheet structure that contributes to the rigidity 
and strength of SF.[49] The fabrication of SF-based scaffolds is 
dependent on the control of crystalline/amorphous structure 
of SF to obtain better mechanical strength, degradation, and 
aqueous processability.[27a]
HA is mostly found in connective tissues and in synovial 
fluid, and it is characterized by its biodegradability, biocompat-
ibility, and viscoelastic properties.[28a,b] Nonetheless, HA has 
limited mechanical strength, which can be solved by chemical 
modification or by crosslinking.[50]
Chitosan is obtained from the N-deacetylation of chitin, and 
consists of d-glucosamine (deacetylated unit) and N-acetyl-
d-glucosamine (acetylated unit) randomly-distributed within 
the polymer and linked by β-(1-4)-glycosidic bonds.[51] It has 
a polyelectrolyte and cationic nature, good biodegradability, 
antithrombogenic and hemostatic action, mucoadhesion, anal-
gesic effect, and antifungal activity.[29a] GG is a water-soluble 
and high molecular extracellular polysaccharide, obtained from 
the organism Sphingomonas elodea (originally denominated 
Pseudomonas elodea). It is biocompatible, thermo-responsive 
with excellent strength and stability, being often used as a 
gelling agent.[52] GG can be obtained in low and high acyl 
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forms, where low acyl GG forms hard, non-elastic and brittle 
gels, while high acyl form results in soft, elastic and flexible 
gels.[30a] Alginate, usually found in brown algae cell walls, is 
seen as a gelling and viscosity agent, with water-uptake ability. 
Its gelation, biocompatibility, biodegradability, and mechanical 
strength can be modulated by combining alginate with different 
bioactive molecules.[31a]
2.3. Synthetic Polymers
The primary motivation in using biodegradable synthetic poly-
mers is related to their very high strength and stiffness, which 
is required for bone repair/regeneration. One concern of such 
type of polymers is that they can undergo a bulk erosion pro-
cess causing premature failure of scaffolds and even an abruptly 
release of acidic degradation products that could trigger a 
strong inflammatory response. However, molecular weight, 
chemical composition, and crystallinity can be manipulated to 
allow a controlled degradation rate.[53] Poly α-hydroxy acids, 
such as PLA, polyglycolic acid (PGA), poly-lactic-co-glycolic 
acid (PLGA) copolymers, and poly PCL are the biodegradable 
polymers mostly used in BTE, in part due to their ability of 
self-reinforcement to achieve a final better strength.[6c,32a] 
Biodegradable polymers typically show less inflammatory 
response when combined with bioceramics.[33a]
PLA is characterized by thermal stability, cytocompat-
ibility, and non-toxic degradation products. It exists in dif-
ferent forms, such as poly-l-lactide acid (PLLA) and poly-
d-lactide acid (PDLA), which L/D ratios can be tuned in order 
to optimize the degradation rate of the materials.[54] PLGA, a 
combination of PGA and PLA, is an FDA approved polymer, 
with very good biocompatibility, biodegradability, and tunable 
mechanical properties.[55] PCL has also been used in bone 
repair with FDA approval, is characterized by its good solubility, 
low melting point, and exceptional blend-compatibility.[56] It 
has good mechanical properties and can be easily processed in 
comparison to PLA and PGA.[57] Particularly, it is very useful 
for long term implantable devices development, owing its slow 
degradation rate. The degradation of polyesters is dominated by 
nonenzymatic hydrolytic scission of ester linkages, therefore 
PCL can take as long as 3–4 years for complete degradation 
due to its higher hydrophobicity, while PGA degrades in 
1.5–3 months and PLLA degrades in 6–24 months.[58] However, 
its hydrophobic nature is unfavorable for cell attachment and 
infiltration, which can be solved by combining with different 
bioceramics and biopolymer coatings.[59]
2.4. Inorganic–Organic Composite Biomaterials
Inorganic–organic composite materials are a good strategy to 
mimic the bone tissue, which is itself a natural composite, with 
mechanical and biological properties significantly better than 
the single components. An optimal ratio between inorganic 
and polymeric materials is critical to induce bone tissue forma-
tion, while keeping the porosity and mechanical strength of the 
composites. A wide range of different combinations gives rise 
to composites with very good performance for BTE.[27d,29d,35c,g,60] 
For example, using SF combined with β-TCP presented high 
pore interconnectivity, cell attachment, and proliferation, and 
adequate in vivo response for BTE.[35a,b] Another study have 
shown that combining biphasic calcium phosphate (BCP) 
and collagen resulted in higher new bone formation than 
BCP alone.[35c] Furthermore, that authors reported that higher 
HAp:β-TCP proportion in the composites positively influenced 
new bone formation. For example, inorganic nanoparticles 
have been also incorporated into polymer matrices to optimize 
their physical and mechanical properties.[21e,29d,61]
3. Scaffolding Fabrication Methods
An array of processing techniques has been developed for 
tissue engineering and consequently, has been applied to BTE 
(Table  2). Ideally, the optimal fabrication technique can pro-
duce repeatable scaffolds with a controlled hierarchal porous 
structure, as the geometry of the pores structure has pro-
found effects on both mechanical and biological response of 
bone tissue.[62] Nowadays, the fabrication technologies that 
can facilitate inclusion of cells and growth factors are highly 
fashionable for optimal scaffold creation.[63] It is certain that 
advanced processing techniques which facilitate the production 
of highly customizable scaffold geometries for patient specific 
implants, are required for specialized clinical needs. Current 
methods for producing bone tissue scaffolds can include: i) 
electrospinning, ii) freeze drying, iii) 3D printing or additive 
manufacturing (AM), iv) phase separation, v) gas foaming and 
vi) particulate leaching (Table 2). Some of these techniques can 
be broken down into further subcategories, for example AM 
can be subdivided into fused deposition modelling (FDM), 
direct ink writing (DIW), stereolithography (SLA), digital light 
processing (DLP), and selective laser sintering (SLS).
The functionality and operating methods of three most 
promising techniques for the future are discussed as follows.
3.1. Electrospinning
Electrospinning involves a process in which a stream of an 
electrically-charged polymer in a viscous state or solution is 
drawn into fiber due to electrostatic forces.[70] A basic electrospin-
ning apparatus is comprised of four main parts: i) syringe pump, 
ii) power supply, iii) metallic needle to allow the electricity to 
move into the polymeric solution, and iv) metallic collector for 
fiber collection.[64b] A scaffold is typically created by connecting 
the spinneret and fiber collector to opposite ended electrical ter-
minals. The potential difference between terminals causes the 
material to be drawn out and deposited onto a collector, which 
facilitates the fabrication of fibers in the nano scale.[6a] Collagen 
and gelatin nanofibers with high porosities with high surface 
areas are typically processed via electrospinning.[71]
3.2. Freeze Drying
Freeze drying or lyophilization, is based on the drying of poly-
meric solutions. It can be broken down into a three-step process: 
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i) solution preparation, ii) casting or molding of the solution, 
and iii) freezing and drying at low pressure. During the third 
step, the ice and the unfrozen water are extracted by subli-
mation and desorption, respectively. Freeze drying is capable 
of producing scaffolds with approximately 90% porosity and 
pore sizes ranging from 20 to 200 µm. Pore size is controlled 
by freeze rate, polymer concentration, and temperature.[7b] In 
order to produce a scaffold with high porosity and interconnec-
tivity a high strong vacuum is required.
3.3. Bioprinting
Bioprinting is unique as it creates layered complex and 
customizable geometries, via 3D digital models produced with 
the computer-aided design (CAD) software.[72] This emerging 
technology is able to produce geometries with controlled 
architecture and porosity, tunable structural and mechanical 
properties, all while being reproducible, and cost-effective. 
Furthermore, cells, bioactive molecules, and/or drugs can be 
Table 2. Description, properties, biomaterials, porosity, and structure/processing of typical fabrication methods used for BTE.
Fabrication 
methods
Description Biomaterials Properties Resolution/
porosity
Structure-processing Ref.
Electrospinning Use of electrostatic 
forces to produce  
fibers
Gelatin, collagen, and PCL Fast, control over: porosity, 
fiber diameter, and pore size;
Post-fabrication structural 
details difficult to maintain
100 nm to 6 µm 
(fiber diameter), 
80–95%
Very slow production, 
reduction in pore size 
with fiber thickness
[6a,c,7b,9e,12,64]
Freeze drying Use of a dehydration 
process to remove 
solvent from a frozen 
solution
Natural or synthetic polymers,  
natural/synthetic-inorganic  
composites (e.g., gelatin/HA,  
collagen/HA)
No leaching phase, easy con-
trol of porosity;








AM: SLS Layer-by-layer laser 
curing process
Synthetic polymers, polymer- 
ceramic/inorganic composites  
(e.g., PCL/TCP, PLLA/Mg,  
PCL/HA)
A broad variety of biomaterials, 
no need for assistance and 
post-processing; Thermal 
distortion that can cause 
shrinking and warping issues
50–100 µm Elevated processing 
temperatures
[6a,10c,12,64c,66]
AM: SLA Laser/photo curing of 
photosensitive resin




High accuracy, complex 3D 
structure, cell inclusion;
Limited to photosensitive resin; 
layers cause stair-stepping 
instead of smooth surface





AM: FDM Layer-by-layer 
deposition of heated/
melted filament
Synthetic polymers (e.g., PCL,  
PLA, PLGA)
High porosity, complete pore 
interconnectivity, control over 
porosity, and pore size; print 
quality is not as good as SLA or 
SLS; limited to thermoplastic 
polymers; problems with 
warping and minor shrinking




Bioprinting Co-extruded filament 
with a cell-laden gel 
to produce a layer by 
layer construct
Natural and synthetic polymers  
with inorganic additions  
(PCL, HA, alginate, SF, chitosan,  
GelMA, varying cell types)
High porosity, complete pore 
interconnectivity, control over 
porosity and pore size; print 
quality can be difficult to control
100–150 µm Challenge balancing bio-
logical and mechanical 
properties for limited 





Use of thermal energy 
to induce separation of 
a polymer solution
Limited material selection  
across synthetic polymers only
No reduction in molecular 
activity; Long time to sublime 
solvent; possible solvent 




Only suitable for ther-
moplastics, difficulties 
in monitoring scaffold 
structure
[12,38,64a,b]
Gas foaming Use of inert gas, high 
pressure and freeze 
drying
Typical BTE natural or synthetic  
polymers, synthetic-inorganic  
composites (e.g., PLA/HA,  
chitosan/HA, PLGA/HA)
Generate structures with a 






ture not explicitly 
defined, closed pore 






cast into a mold and 
solvent removed by 
lyophilization
Typical BTE natural or synthetic  
polymers
Salt/polymer ratio can control 
pore size; possible residues 
of solvent or salt particles; 





dispersion of pores, lack 
of pore inner connec-
tivity, difficulty in fabri-
cating thick scaffolds
[6c,64c,65a]
AM = additive manufacturing; SLS = selective laser sintering; SLA = stereolithography; FDM = fused deposition modeling.
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incorporated into the structures to yield better cellular response. 
A diversity of natural and synthetic polymers, bioceramics, and 
their combinations have been used for bioink production, while 
collagen and its derivatives are the most commonly used for 
cell-laden solutions.[73]
Bioprinting can be split up into the following steps: i) pre- 
processing; ii) processing; and iii) post-processing. Pre- 
processing refers to imaging of the anatomic structure of 
the target tissue by means of computerized tomography (CT) or 
magnetic resonance imaging (MRI) scans and translating those 
images to sliced 3D models.[74] The processing step encompasses 
everything that is involved in the production of the bioprinted 
tissue, that is, bioink development and scaffold fabrication. Post-
processing refers to the maturation of the bioprinted tissue until 
suitable for in vivo usage, typically taking place in a bioreactor.
Several requirements should be considered for printable 
bioinks, such as rheological behavior (viscosity and shear thin-
ning), surface tension, swelling, gelation kinetics, and mechan-
ical properties of the materials.[75] Another important aspect is 
the bioinks crosslinking—physical, chemical, or enzymatic—
during the processing and post-processing steps, to preserve 
the biomechanical stability of the printed structures/constructs. 
Physical crosslinking depends on temperature and molecular 
interactions to create  non-covalent bonds  and organic free 
radical species. Examples of physical crosslinking are the use 
of divalent ions (e.g., Ca2+, Ba2+, and Mg2+) to crosslink algi-
nate.[76] Chemical crosslinking is obtained by the formation of 
covalent bonds between polymer chains, and it is more stable 
and stronger than physical crosslinking.[77] Glutaraldehyde 
(GTA), 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydro-
chloride (EDC), and 1,4-butanediol diglycidyl ether (BDDGE) 
are the most common crosslinkers for functional groups of 
the polymers (e.g., COOH, OH, or NH2).[78] Enzymatic 
crosslinking also promotes the covalent bonding between 
protein-based polymers, with rapid gelation (no more than 
10 min) under physiological conditions.[76] Diverse enzymes 
have been used for gelation in situ, such as transglutaminase, 
sortase, lysyl oxidase, plasma amine oxidase, phosphopanteth-
einyl transferase, phsosphatases, β-lactamase, thermolysin, and 
peroxidases.[76,79] Among them, horseradish peroxidase (HRP) 
has particular interest for the biomedical field, owing to its fast 
gelation and controllable crosslinking density. HRP catalyzes 
the coupling of aniline, phenol and tyramine in the presence of 
an oxidizer, such as hydrogen peroxide (H2O2).[80] One example 
is HRP/H2O2 to crosslink SF, when combined with elastin, is 
proposed as fast-setting bioinks for hydrogels bioprinting.[81] 
Methacrylation of biopolymers is another chemical modifica-
tion widely applied to tailor their mechanical and biofunction-
ality. For example, gelatin methacrylate (GelMA) is derived by 
the reaction of gelatin and methacrylic anhydride in the pres-
ence of a photoinitiator (e.g., Irgacure 2959).[82]
In scaffold-based (top-down approach) bioprinting, an exog-
enous biomaterial matrix, such as a hydrogel, is printed and 
cells are either seeded or printed as part of the bioink.[83] Top-
down approaches to printing are commonly studied for bone 
tissue as they are likely to achieve the structure and mechanical 
performance required for bone.[84] SLA, SLS, and FDM are the 
most prevalent forms of bioprinting used in BTE. In order to 
overcome challenges such as low cell seeding efficiency and 
deficient cellular distribution, biomimetic hydrogels that encap-
sulate regenerative cells within the external matrix are often 
used. These hydrogels have shown promising capabilities to 
fulfil the needs for cell viability, cell anchorage, cell delivery, 
as well as chemical cues for sustained release of growth fac-
tors.[85] Cellular printing often adopts a scaffold-free (bottom-
up) approach which relies on cell aggregates to fuse together 
by means of autonomous self-assembly. The techniques used 
for cellular printing are droplet-based bioprinting (adapted 
from DIW), extrusion-based bioprinting (adapted from FDM), 
and laser-assisted bioprinting. Current bioprinting techniques 
are primarily dominated by single components bioink, which 
often lack of an acceptable trade-off between cell viability 
and printer processability.[86] These techniques are not suit-
able for printing large bone scaffolds but for smaller tissue 
with high cell densities. Interestingly, hybrid approaches have 
been explored showing promising achievements with respect 
to simultaneously addressing mechanical and biological 
functions.[87]
3.4. Decellularization
Decellularized bone matrix (DBM) has been widely used in 
BTE as scaffolds and as bioinks for biofabrication, aiming 
to mimic the native bone microenvironment.[88] Decellu-
larization involves the removal of all cells from tissue, while 
retaining the native ECM composition and its architectural 
integrity, and its ability to promote cell growth and differ-
entiation. Processing techniques to obtain DBM include 
surfactants and enzymatic methods (e.g., ethylenediaminetet-
raacetic acid in combination with trypsin or sodium dodecyl 
sulfate (SDS) with ammonium hydroxide, Triton X-100, and 
sodium deoxycholate, and nucleases and proteases), as well 
as thermal shock, sonication, and hydrostatic pressure.[89] 
The latter has the advantage of no harmful chemical usage 
and minimization of protein denaturation, thus a high level of 
ECM content can be preserved.[90] Final steps involve the use 
of nucleases and dehydrated alcohol for a complete removal of 
cellular remains. Decellularization is confirmed by measuring 
DNA content and by cell nuclei staining.[91]
DBM-based scaffolds can be fabricated by DBM alone or 
in combination with a variety of polymers and bioceramics to 
enhance its mechanical performance, osteogenesis, and vascu-
larization potential.[88b,d,92]
4. Scaffold Structure/Function Properties in Bone 
Tissue Engineering
Bone tissue architecture is a critical feature in BTE, as structure 
influences both mechanical properties and biological response. 
While performing the load-bearing functions of the native bone, 
the scaffolds should also facilitate vascularization.[93] The inter-
connected porous structure of the scaffolds (Figure  3) allows 
native cells to migrate and proliferate.[5] In addition, an optimal 
design should provide sufficient surface area for cell–scaffold 
interactions, while facilitating oxygen and nutrient diffusion, as 
well as the expulsion of waste products.[94]
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Typically, a pore size of ≥300 µm is required to facilitate 
new bone formation and vascularization, while the minimum 
accepted size is ≈100 µm.[95] Larger pore size proves to be optimal 
for bone growth due to the sufficient space provided for oxygen 
and nutrient supply, that further facilitated vascularization in 
new bone tissue.[96] Typically, pore sizes for BTE scaffolding are 
in the range of 50 to >900 µm.[5] Macropores have been shown 
to promote osteoinductivity by mediating vascularization.[97] 
However, pore sizes of less than 100 µm may prevent angiogen-
esis.[98] An average pore size of 550 µm has proven to be optimal 
for bone formation, while hierarchical porous structures have 
been shown to enhance biological properties.[5] Percolation 
theory, as shown in Figure 3A, is used to calculate the diameter 
of the largest tracer that can cross the interconnected pores of a 
scaffold. The percolation diameter is critical for understanding 
the interconnection of a scaffold as it limits the size of cells and 
nutrients that can pass through the scaffold.[5] The bottleneck 
dimension, on the other side, indicated by brackets in Figure 3B, 
describes the diameter of connections between pores. An in vivo 
study revealed that the optimal pore/bottleneck dimension for 
bone substitutes is 700–1200 µm range and therefore, it can be 
controlled by printing technologies.[99]
Tissue engineered bone needs to have sufficient compres-
sive strength to support bodyweight. Typically, the compres-
sive modulus for trabecular bone and cortical bone ranges 
from up to 2.0 GPa and 14–18 GPa, respectively.[7b] The elastic 
modulus of fabricated scaffolds, on the other hand, also needs 
to be high enough to maintain its structure in vivo and to 
facilitate cell growth.[100] The degradation rate of the scaffold 
must match the growth of native ECM, to ensure mechanical 
support throughout the lifecycle of the scaffold. This is largely 
dictated by the rate of fluid ingress, which in turn is a function 
of porosity.[101] Therefore, increased porosity positively impacts 
scaffold degradation at the cost of decreased mechanical prop-
erties.[102] The typical inverse relationship between porosity and 
compressive strength for bone tissue scaffolds is demonstrated 
in Figure  4. Pore interconnectivity, pore size shape play an 
important role in the fabrication of an ideal scaffold for bone 
tissue repair. Considering that the tissue repair rates decrease 
with age, the scaffold structural design and material selection 
should be carefully considered.[7b]
Bioprinted bone scaffolds can allow the fabrication of 
engineered tissues with controlled physical and mechanical 
properties, combining multi-bioink printing, and printing in dif-
ferent layers and gradients.[63b,88d,104] For example, mechanically 
strong ‘cancellous bone-like’ printable implants, containing stem 
cells encapsulated in PLGA microparticles and controlled-release 
of programming factors, help the development of novel localized 
delivery strategies to direct cellular behavior for bone repair.[104g]
Regarding the use of dECM-based scaffolds for BTE, ideal 
microenvironments with instructive biological molecules 
Figure 3. Schematic of A) percolation theory and B) bottleneck dimension in a scaffold. Reproduced with permission.[5] Copyright 2020, Elsevier.
Figure 4. Compressive strength, porosity, and morphologies of chitosan/
carboxymethyl cellulose (CS/CMC) nano-biocomposite scaffolds, nano-
composite scaffolds containing 0%, 1%, 2.5%, 5%, and 10% CCNWs-
AgNPs (carboxylated cellulose nanowhiskers decorated with silver 
nanoparticles) were termed as SCA-0, SCA-1, SCA-2.5, SCA-5, and SCA-
10, respectively. Reproduced with permission.[103] Copyright 2018, Elsevier.
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and reduced immune responses have been reported.[105] For 
example, in vitro studies show that rat BMSCs proliferation 
and differentiation along the osteoblastic lineage on PCL/decel-
lularized bovine small intestinal submucosa/HAp multilayered 
scaffolds after 21 days of culture, while retaining mechanical 
performance.[105b] Parallel to these studies, bioprinting of dBM-
based scaffolds have received considerable attention showing 
that precise pore size and microporosity can allow tuning of 
vessel infiltration, which leads to new bone formation, as well 
as enhanced mechanical stability.[88d,92c,104d]
5. Scaffold Structure/Processing Relationships 
in Bone Tissue Engineering
Control of the structure ultimately controls the mechanical 
properties and to a lesser extent the biological response. There-
fore, it is crucial to evaluate which fabrication method can 
provide the most control over the structure to mimic native 
tissue. While key aspects of scaffold structure including pore 
size, shape, orientation, and interconnectivity are directly 
determined by spatial resolution and geometric control of a 
processing method, they are indirectly influenced by processing 
time, crosslinking mechanisms, and thermal degradation. For 
example, gelation rate is crucial in order to set suitable printing 
speeds that ensure scaffold stiffness is maintained throughout 
processing and post processing, therefore gelation of a bioink 
needs to be analyzed by examining its chemical, physical, or 
enzymatic crosslinking mechanisms prior to printing.[106]
While Table 2 provides insight into the current state-of-the-
art fabrication techniques, this does not necessarily provide a 
simple answer to the question of—which technique will become 
dominant for BTE? For example, spatial resolution is intrin-
sically linked with mechanical and biological properties and 
therefore a key factor, but this needs to be considered within 
certain context. Comparing additive manufacturing methods, 
a higher resolution (roughly 15 µm) can be obtained by inkjet 
bioprinting of ceramic scaffolds suitable for large bone con-
structs, however this technique is limited by its incompatibility 
with cellular printing. Another example is that cortical bone 
typically has a porosity of only 5–10%, while cancellous bone 
contains a porosity of 50–90%, therefore applicable techniques 
must facilitate creation of porosities across these ranges.[104e]
To date no processing technique is capable of constructing 
architectures identical to that of native bone tissue, however 
this is expected to be change with the development of advanced 
health care materials that facilitate micro-extrusion without 
nozzle clogging, which will provide high levels of spatial 
resolution.[104e] Other processing issue and limitations are likely 
to be resolved through combining techniques, as for example 
AM, which can be combined with particulate leaching or freeze 
drying to overcome the material or structural based limitations.
5.1. Clinical Trials
It is worth noting that an optimal biomaterial has yet to be 
established for BTE, therefore a comparison across fabrication 
techniques still lacks the merit of a likewise comparison across 
optimal bone tissue materials. So far, limited bone tissue scaf-
folds have made their way into the clinical use, while this fails 
to provide key insights to the structure-processing relation-
ship, it provides a meaningful context with regards to optimal 
material selection. Zeng et  al.[107] reviewed studies of clinical 
trials for the repair of bone defects, eight of which used natural 
scaffolds (collagen and gelatin) and twelve focused on synthetic 
scaffolds. It was reported that combining scaffolds with bone 
stimulating agents expedited bone healing, with HAp/collagen 
showing the highest grade of bone regeneration. Among few 
clinically available products, composites that consist of natural 
biopolymers (both collagen and gelatin) and inorganic additives 
such as TCP and HAp tend to dominate the market.[17]
5.2. Hierarchical Structures
As shown in Figure 5, since bone regeneration is conducted by 
the synergistic effect of cells and scaffolds, numerous studies 
Figure 5. The hierarchical pore structure of bone tissue. Reproduced with permission.[62c] Copyright 2018, MDPI.
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in BTE have adopted the strategy of mimicking the hierarchical 
pore structures of bone tissues.[62c,104b,108] Using a combined 
method of indirect 3D printing and freeze-drying, created a 
hierarchical 3D bioactive scaffold that consisted of SF and 
bioactive glass, which exhibited two levels of pores in the order 
of 500–600 and 10–50 µm. This yield an excellent mechanical 
stability and flexibility, that the hierarchically porous scaffold 
did not exhibit any fluctuation after compression loading in a 
wet condition. Moreover, the biocomposite scaffold promoted 
the attachment of human bone marrow stem cells, as well as 
the alkaline phosphatase (ALP) activity as compared to plain SF 
scaffold, highlighting the promise of hierarchical structures in 
BTE applications.[104b]
Complex morphologies which better mimic the native bone 
tissue tend to have greater mechanical properties. For example, 
PCL/PLGA scaffolds show varying Young’s moduli for different 
scaffold morphology: diagonal (9.81 MPa), staggered (7.43 MPa), 
and lattice (6.05 MPa).[109] A less reported structural feature, 
which has a distinct and measurable effect on mechanical prop-
erties, is pore orientation. This has been examined on chitosan 
and gelatin (type B) scaffolds fabricated by sequential unidirec-
tional freezing. It was found that compressive, tensile, and shear 
moduli all show the same trend based on pore orientation, that 
vertical > random orientation > horizontal.[110] This further adds 
speculation to the processing technique that can create scaffolds 
with controlled pore orientation aligned to that of the native 
bone tissue. These efforts have concentrated on combining 
AM with other traditional tissue engineering approaches such 
as gas foaming[111] and these methods have shown porosity and 
geometrical control can be achieved simultaneously.
Kim et  al.[112] fabricated magnesium phosphate (MgP) 
ceramic scaffolds of varying pore sizes (macro and micro) using 
a combination of 3D printing and salt-leaching and investigated 
the in vivo response in rabbit calvarial model. Three types of 
scaffolds were created, all with macropores (>100 um) present 
but varying levels of micropores (Figure  6A). MgP scaffolds 
containing micropores show a lamellar morphology with higher 
porosity (Figure 6B), which promotes faster biodegradation that 
appears to enhance bone formation and remodeling activities, 
when compared to MgP0 (Figure 6C).
Liu et al.[113] reported the impact of differing levels of pores 
on vascularization in adult rabbits, using poly(3-hydroxybu-
tyrate-co-3-hydroxyhexanoate) (PHBHHx) scaffolds fabricated 
by combined solvent-casting and particulate leaching methods. 
While previous studies have primarily looked at porous struc-
tures at a macro- and micro-level, Liu et  al. demonstrated the 
ability of mesoporous materials (2–50 nm) to: i) stimulate the 
formation of HAp, ii) promote proliferation and differentiation 
of osteoblasts, and iii) increase bone-matrix interface strength. 
Furthermore, the incorporation of mesoporous materials was 
is beneficial for delivering growth factors such as BMP-2 and 
promotes angiogenesis which further enhanced bone regenera-
tion, as depicted in Figure 7.
While most fabrication techniques covered in this review 
are capable of producing a combination of micropores and 
macropores, increased spatial resolution and accuracy are 
Figure 6. Effect of the biodegradation rate controlled by pore structures in magnesium phosphate (MgP) ceramic scaffolds on bone tissue regeneration 
in vivo: A) MgP scaffolds with varying micropore sizes; B) MgP scaffolds were implanted in the rabbit calvarial defect area (4 mm), and the calvarias 
were decalcified, sectioned, and stained with hematoxylin and eosin (H&E) after 4 and 8 weeks; C) Bone area and “bone + marrow-like tissue” area 
at 4 and 8 weeks post-surgery, ∗p < 0.05, ∗∗p < 0.01. #p < 0.05, #p < 0.01 versus hole group. Reproduced with permission.[112] Copyright 2016, Elsevier.
Adv. Funct. Mater. 2021, 2010609
www.afm-journal.dewww.advancedsciencenews.com
2010609 (11 of 22) © 2021 The Authors. Advanced Functional Materials published by Wiley-VCH GmbH
required to consistently produce highly controlled mesopores. 
Zheng et al.[114] demonstrated the application of metal injection 
molding (MIM), a near-net forming fabrication method, on the 
fabrication of titanium implants. This facilitates accurate rep-
resentation of the porous structure of native bone tissue, down 
to the mesopore level, and this has proved to be beneficial in in 
vivo osteogenesis canine models. Although titanium, as a bio-
stable and bioinert material, used for long-term implantation, 
is largely out of scope for this review, this manufacturing tech-
nique still provides insight on the benefits of precise control 
over structure in BTE.
6. Advanced Strategies for Improving Vascularization 
of Scaffolds in Bone Tissue Engineering
Vascularization is the most crucial challenge in BTE, since 
tissue thickness limits nutrient and oxygen diffusion, which is 
required to support osseointegration and osteogenesis during 
bone healing and regeneration (Figure  8).[115] Angiogenesis is 
known to influence osteogenesis, where bone progenitor cells 
and osteoblasts are near vascular endothelial cells during new 
bone formation, particularly in critical-sized defects.[116] Vas-
cular endothelial growth factor (VEGF) is the major growth 
factor for vascular growth and it is required to effectively 
couple angiogenesis with osteogenesis during bone repair/
regeneration.
Various strategies to develop an appropriate vascular net-
work in engineered scaffolds have been explored, namely: i) 
use of biocompatible materials in scaffold design; ii) micro-
nano structure, morphology, and porosity, and roughness 
of the scaffolds, as described in Section  5; iii) ion-doped 
materials; iv) addition of angiogenic growth factors (e.g., VEGF 
and fibroblast growth factor (FGF)) or recombinant proteins; 
and v) co-culture cell systems in static and dynamic conditions 
(Table 3).[104c,f,118]
The fabrication of β-TCP and osteogenic peptide (OP) con-
taining water/PLGA/dichloromethane (DCM) emulsion inks 
scaffolds using cryogenic 3D printing was reported as vasculari-
zation approach for BTE.[104f ] Scaffolds were then coated with 
angiogenic peptide (AP) containing collagen type-I hydrogel to 
ensure angiogenic capability (Figure 10A). In vitro angiogenesis 
tests using rat endothelial cells (ECs) seeded on the scaffolds 
showed a viability of 98% with alive cells after 3 days of culture 
(Figure  10B-a,b). It was also observed enhanced EC migration 
on the extracts of the scaffolds containing AP, due to its fast 
release (Figure 10B-c,d).
The strategy involving the incorporation of bioactive ions 
(e.g., Mg, Ce, and Cu) in the materials led to increased levels 
of angiogenic and osteogenic markers.[104c,120] Gu et  al.[104c] 
prepared Mg-doped β-TCP scaffolds cultured with human 
bone marrow mesenchymal stem cells (hBMSCs) and human 
umbilical vein endothelial cells (HUVECs) to achieve bone 
formation and favorable vascularization potential. Also, Ma 
et al.[120a] reported a significantly improvement of vascularized 
bone formation on Mg-doped 3D-printed tantalum scaffolds. 
Another reported approach is the incorporation of Ce nano-
particles in PLLA/gelatin composite scaffolds obtained through 
electrospinning.[120b] Chick embryo chorioallantoic membrane 
(CAM) as an in vivo model system for angiogenesis evaluation 
showed a considerable increase of embryonic blood vessels, 
when treated with VEFG. Another way to deliver bioactive 
ions with crucial role in vascularization and osteogenesis, is by 
using bioactive glasses biomaterial scaffolds.[120d,124] The release 
Figure 7. Schematic diagram of the effects of scaffold hierarchy on the bone regeneration. Reproduced with permission.[113] Copyright 2020, Elsevier.
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of ions presented within bioglasses chemical structure, during 
network dissolution, can activate different genes associated 
with vascularization and bone formation.[125]
Co-culture of angiogenic cells with pluripotent stem cells has 
positive effects on new blood vessels formation and osteogen-
esis, as another vascularization strategy.[118b,122] For example, 
He et  al.[118b] observed that ASC/endothelial progenitor cells 
(EPCs) co-culture system combined with HAp scaffold signifi-
cantly promoted regeneration and angiogenesis of critical-sized 
bone defects. In a study by Honda et al.,[122a] HAp-fiber scaffolds 
combined with connective tissue growth factor (CTGF), under 
co-culture of HUVECs and MC3T3-E1 cells, exhibited enhanced 
osteogenesis via stimulation of angiogenesis. Thrivikraman 
et  al.[122b] developed a cell-laden collagen hydrogel, encapsu-
lating co-culture of HUVECS and BMSCs, able to stimulate the 
osteogenic differentiation of hMSCs, while enabling the forma-
tion of hMSC-supported vascular capillaries in vitro and in vivo. 
Markou et al.[122c] fabricated vascularized tissue using endothe-
lial cells, smooth muscle cells and pericytes (vascular organoids) 
embedded in collagen/fibrinogen/fibronectin hydrogels, useful 
as a starting point for capillary-like structures sprouting in vitro 
and a fast creation of a functional vascular network in vivo.
Figure 8. Angiogenesis coupled with osteogenesis during intramembranous ossification: A) Physiological levels of vascular endothelial growth factor 
(VEGF) maintain bone homeostasis. Low VEGF interrupts osteoblast differentiation and high VEGF increases osteoclast recruitment, leading to bone 
resorption; B) Migration and proliferation of endothelial cells during bone repair, and secretion of bone morphogenetic protein (BMP)-2 and BMP-4; 
C) VEGF dose dependently regulates Sema3A expression in endothelial cells and Sema3A from different sources suppresses osteoclast differentiation 
and stimulates bone deposition; D) Sema3A is also responsible for the recruitment of neuropilin 1-expressing (Nrp1+) monocytes, promoting vessel 
stabilization. Reproduced with permission.[117] Copyright 2017, Frontiers Media SA.
Table 3. Vascularization strategies for BTE.
Strategies Outcomes Schematic representation Ref.
Scaffold architecture Cellular adhesion, proliferation, and differentiation Figure 9A [119,113]
Biomaterials incorporating bioactive ions Activation of different genes related with vascularization and bone formation Figure 9B [104c,120]
Angiogenic growth factors Short-term with burst release profiles; VEGF initiates macrophage-related 
angiogenic response in the inflammation stage;
FGF, TGF, BMP, IGF, PDGF, and erythropoietin, growth hormone can induce 
angiogenic response to injury
Figure 9C [118c,121]
Co-culture systems in static and dynamic 
conditions
MSCs/ECs enhances the formation of capillary-like structures; Smooth muscle 
cells facilitate vessel stabilization
Figure 9D [118b,122]
BMP: bone morphogenetic protein; ECs: endothelial cells; FGF: fibroblast growth factor; HGF: hepatocyte growth factor; IGF: insulin-like growth factor; MSCs: mesen-
chymal stem cells; PDGF: platelet derived growth factor; TGF: transforming growth factor; VEGF: vascular endothelial growth factor.
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A different strategy aiming to reproduce an autologous vas-
cularized BTE were designed using PCL nanofibers (NFM) 
comprising bound endogenous bone morphogenetic pro-
tein-2 (BMP-2) and VEGF on their surface.[118c] Chick CAM in 
vivo assay have showed high mature blood vessels with highly 
branched capillary network formed in the systems containing 
endogenous VEGF (VEGF and BMP2|VEGF), after 7 days of 
implantation (Figure 11).
7. Immunomodulatory Scaffolds in Bone  
Tissue Engineering
Scaffolds with ability to regulate host-to-scaffold immune 
response with immunomodulatory properties can employ a 
regenerative potential to a varied extent.[126] The activation of 
immune cells is important in regulating the balance of bone 
reconstruction and resorption in pathological conditions.[127] 
Among immune cells, macrophages are responsible for phago-
cytosis and recruitment of other cells crucial in the tissue 
healing process.
The physicochemical properties of the biomaterials, such 
as shape, size, porosity, and chemical functionality, as well 
as the type of biomaterial, can stimulate the immune or 
inflammatory pathways,[128] and ultimately to facilitate new 
bone formation.[129] Wang et  al.[126c] fabricated magnetic lan-
thanum (La)-doped HAp nanoparticles/chitosan scaffolds 
(MLaHA/CS) capable of recruiting rat bone marrow mesen-
chymal stem cells (rBMSCs) and modulating host-to-scaffold 
immune responses through macrophage polarization, for 
bone regeneration. The scaffolds presented interconnected 
macropores with plate-shaped nanoparticles and ≈50–
150 nm width and ≈30 nm thickness. It was observed that 
the magnetic nanoparticles and La dopants can inhibit the 
differentiation of macrophages toward M1, thus decreasing 
the inflammatory response and promotes M2 macrophage 
polarization, providing a pro-regenerative microenvironment 
for bone repair (Figure  12A). In vivo tests performed in rat 
calvarial defect mode showed high new bone formation in 
the MLaHA/CS group in comparison to the other composi-
tions (Figure 12B).
Another interesting approach is the use of CaPs-based 
biomaterials to trigger desired immune responses and to 
enhance bone healing, mainly due to the osteoconductive 
capacity of CaPs.[129b,130] Furthermore, the CaPs structural 
features can strongly influence specific cell responses. For 
instance, nanoscale calcium deficient HAp (CDHA) can stim-
ulate osteogenesis, while high porosity can positively modu-
late its inflammatory capability.[130d] Additionally, combining 
CaPs with MSCs highlight the main role of the host immune 
system for regeneration of bone.[129b] On the other hand, β-
TCP seeded with macrophages presented reduced pro-inflam-
matory cytokines in comparison to CDHA biomaterial.[130a] 
Recently, scaffolding strategies comprising β-TCP function-
alized with bioactive ions able to modulate the biological 
responses of bone have been proposed.[27d,35b,131] For instance, 
biocomposites made of β-TCP doped with Mn2+, Zn2+, and/
or Sr2+ in combination with SF presented biological responses 
according to the specific ionic dopant.[131] While Sr2+ and 
Mn2+ doping showed high osteogenesis, scaffolds doped with 
Zn2+ enhanced cell proliferation, thus showing capability of 
promoting immunomodulation.
Figure 9. Schematic representation of vascularization strategies: A) Scaffold architecture; B) Biomaterials incorporating bioactive ions; C) Angiogenic 
growth factors; D) Co-culture systems in static and dynamic conditions. Reproduced with permission.[119,123] Copyright 2018, Elsevier; 2018, MDPI; 2015, 
Frontiers Media SA; 2020, Elsevier; 2018, BMC.
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8. Conclusion and Future Perspectives
It is apparent that both traditional and state-of-the-art means of 
tissue engineering have potential in BTE. Optimal fabrication 
methods must be capable of producing a composite scaffold, 
which can meet the desired tissue characteristics (i.e., struc-
tural stability—porosity, pore size, and pore interconnectivity, 
mechanical properties, biocompatibility, osteoconductivity/
osteoinductivity, and angiogenesis potential), which is still a 
challenge. Only with attention to the relationship between these 
key characteristics and fabrication methodology will be possible 
to develop suitable biomaterials, with hierarchical structure 
identical to natural bone tissue.
While adaptation and realization of scaffold fabrication 
techniques for clinical translation of BTE remains a major 
challenge, with a very limited number of scaffolds being used 
clinically. It is likely that scaffold fabrication methods using 
single material will not take the lead in BTE due to the com-
plex composite nature of bone tissue. Since scaffold structural 
features heavily influence mechanical and biological proper-
ties, processing with random pore orientation and lack of pore 
control will become inappropriate for demanding applications, 
such as large bone replacement. Furthermore, it is now clear, 
that the incorporation of a controlled hierarchal pore structure, 
with interconnected pore networks of defined pore shape are 
critical for the fabrication of bone tissue. Therefore, scaffold 
fabrication will be focused on techniques which can control 
these elements.
Advances in magnetic resonance imaging (MRI), com-
puted tomography (CT), and micro-CT scanning have led 
to the possibility of patient specific structural information, 
which can feedback into the scaffold design loop and be used 
Figure 10. A) Schematic illustration of cryogenic 3D printing of TCP/PLGA/DCM containing osteogenic peptide (OP) and covered by angiogenic pep-
tide (AP); B) Angiogenic study of the scaffolds: a,b) live and dead images of endothelial cells ECs on scaffolds and viability; c,d) EC migration of the 
scaffolds extracts after 12 h of culture. T: TCP/PLGA, TV: AP/collagen/TCP/PLGA, TB: OP/TCP/PLGA, TVB: AP/collagen/OP/TCP/PLG. Reproduced 
with permission.[104f] Copyright 2021, Elsevier.
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to monitor postoperative structural changes. In general, AM-
based techniques are capable of closely producing desired 
scaffold architectures through the utilization of digital twins 
(CAD models). Currently, structural and resolution defi-
ciencies across other techniques are attributed to physical 
limitations within the hardware. While this approach is still 
novel for techniques such as electrospinning, it highlights the 
benefit of the basic principles of AM-based approaches. How-
ever, controlling fiber diameter across complicated process-
based interactions, such as whipping amplitude, electrostatic 
forces, and viscoelastic forces, remains problematic for elec-
trospinning techniques.
Furthermore, combining CAD with statistical techniques and 
finite element analysis (FEA) can provide further insight into 
the relationship of structure and mechanical properties. While 
extrusion-based AM systems have the most promise to replicate 
constructs with predefined internal geometries, they are slow 
and print resolutions are poor due to the physical limitations 
of the system (i.e., nozzle diameter and motion control). Over-
coming these limitations will be critical for BTE to progress, 
candidate methodologies will likely include the combination of 
techniques. Cell viability and perfusion of nutrients throughout 
the full structure will require new bioinks with the incorpora-
tion of microcarriers showing promise. Polymerization-based 
fabrication methods (e.g., SLA) can overcome resolution and 
speed issues; however, new materials must be developed while 
considering their characteristics outlined herein. Among the 
collection of different biomaterials used in the scaffolds fabri-
cation, the combination of polymers and inorganic materials 
are considered the most promising ones. These composite 
materials have better strength, adequate biodegradability, and 
immune response.
In brief, to create bone tissue which mimics the native ECM, 
further efforts are required in the area of structure-processing 
Figure 11. a) Representative photographs of ex ovo CAM after 7 days of implantation; b) Blood vessels quantification; c) Vascular length density (i.e., 
ratio of skeletonized vasculature area to total area); and d) Vascular density (i.e., ratio of vasculature area to total selection area). (*p < 0.01; **p < 0.001; 
***p < 0.0001): a denotes significant differences compared to CTRCAM; b denotes significant differences compared to NFM; c denotes significant differences 
compared to BMP-2; d denotes significant differences compared to VEGF. Reproduced with permission.[118c] Copyright 2020, Royal Society of Chemistry.
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relationships with concurrent material development. Due to the 
inherent limitations mentioned regarding the different fabrica-
tion techniques, combined strategies offer potential. Additive 
manufacturing techniques linked with the latest medical 
imaging techniques offer vast potential over the coming years 
to bring patient specific solutions from the lab to the bedside 
while offering improved patient outcomes.
Regarding the grand challenge of vascularization and 
immunomodulation in BTE, several approaches have been 
successfully reported to induce angiogenesis and osteogenesis. 
Figure 12. A) Detection of M1 and M2 polarization by flow cytometry with macrophages. B-a) Micro-CT analysis of calvarial bone defects after 9 weeks 
of implantation; b) New bone formation determined by fluorochrome-labeling analysis, including casein (green) at week 4 and Alizarin Red (red) at 
week 8; c) The percentages of fluorochrome areas (*p < 0.05); and d) BV/TV, TBN, TBT values in bone defect area (*p < 0.05). BV/TV: bone volume/total 
volume; TBT: bone trabecular thickness; TBN: bone trabecular number. HA/CS: HAp/chitosan scaffolds; LaHA/CS; La-doped HAp/chitosan scaffolds; 
MLaHA/CS: magnetic La-doped HAp/chitosan scaffolds. Reproduced with permission.[126c] Copyright 2020, Royal Society of Chemistry.
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However, effective application of tissue engineered vascularized 
bone grafts in clinics is very limited. Attention should be given 
to properly understand the kinetics of growth factors release 
and the local biomechanical environment. In this context, engi-
neered gradients during scaffold development can open up new 
possibilities for BTE.
Finally, considerations should be placed on biomimetic scaf-
fold design with incorporated immunomodulatory characteris-
tics to enhance in situ bone regeneration for improved clinical 
outcomes.
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